Business
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
Itolizumab treatment associated with high rates of overall clinical response in the treatment of acute GVHD Clinical efficacy of itolizumab associated with
About this update from Equillium, Inc.
[{"type":"text","content":"\nItolizumab treatment associated with high rates of overall clinical response in the treatment of acute GVHD\n\nClinical efficacy of itolizumab associated with higher serum concentrations after a single dose\n\nCD6 confirmed as a target to prevent pathogenic T cell recruitment into inflamed organs\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The hybrid meetings are taking place virtually and in-person at the Salt Palace Convention Center in Salt Lake City, April 23 – 26, 2022.\n\n“The clinical findings presented this weekend were highlighted by rapid and durable responses and a meaningful reduction in the use of corticosteroids that demonstrate the potential clinical value of itolizumab for patients with high-risk aGVHD,” said Dr. Steve Connelly, chief scientific officer at Equillium. “The data also shows an association between itolizumab serum concentration levels and clinical response that highlights the importance of achieving high concentrations early in the treatment period to maximize pharmacodynamic effects and clinical efficacy. The evidence of this activity at the doses evaluated in the EQUATE study were subsequently used to optimize dose selection for the recently initiated Phase 3 EQUATOR study in the first-line treatment of aGVHD patients.”\n\nDr. Connelly continued, “Additionally, translational data presented by our team suggests that the CD6-ALCAM pathway is involved in the migration of T cells through endothelial tissue and demonstrates that blockade of CD6 by itolizumab has the potential to prevent pathogenic T cell recruitment into inflamed organs.”\n\nItolizumab is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of the pathogenic T cells driving a number of immuno-inflammatory diseases.\n\nDetails of Itolizumab Data Presented\n\nTitle: Updated Interim Results from the EQ...